Table 3.

Demographic and clinical manifestations of non- juvenile idiopathic arthritis patients

Cohort (n = 171)	Autoinflammatory diseases	Connective tissue diseases	Vasculitis
Age at the study(y), med (min–max)	11 (4–20)	13 (4–20)	16 (11–20)
Female, n (%)	59 (54.1)	39 (76.5)	4 (36.4)
Disease duration (mo), med (min–max)	55 (9–173)	41 (4–101)	41 (3–125)
Nonbiologic DMARDs Type, n (%); Duration (mo), med (min–max)
Methotrexate	13 (11.9); 16 (3–48)	29 (56.9); 20 (2–36)	2 (18.2); 14.5 (9–20)
Mycophenolate mofetil	–	24 (47.1); 14 (2–48)	1 (9.1); 8
Azathioprine	–	14 (27.5); 12 (5–20)	9 (81.8); 10 (2–36)
Biologic DMARDs Type, n (%); Duration(mo), med (min–max)
Etanercept	5 (4.6); 12 (8–48)	–	1 (9.1); 16
Infliximab	1 (0.9); 9	–	2 (18.2); 6.5 (5–8)
Anakinra	81 (74.3); 3 (1–24)	–
Canakinumab	84 (77.1); 16 (2–75)	–
JAK inhibitors Type, n (%); Duration(mo), med (min–max)
Tofacitinib	–	3 (5.9); 5 (3–10)	–

JIA Juvenile idiopathic arthritis, DMARDs disease-modifying antirheumatic drugs, JAK Inhibitors: janus kinase enzyme inhibitors